The U.S. Food and Drug Administration (FDA) issued a warning letter dated September 18, 2026 to Houston-based Empower Clinic Services, LLC d/b/a Empower Pharmacy and its CEO, Arta Shaun Noorian.
Following a November 3 to 14, 2025 inspection of its Houston facility, the FDA concluded that Empower Pharmacy compounded mass quantities of GLP-1 drug products, specifically tirzepatide and semaglutide formulated with added vitamins (niacinamide or cyanocobalamin), that fail to meet the legal conditions for compounding exemptions under Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Furthermore, inspectors documented significant Current Good Manufacturing Practice (CGMP) and insanitary condition violations, rendering the products unapproved, misbranded, and adulterated under federal law.
For medical directors, medspa operators, telehealth platforms, and compounding prescribers, this enforcement action serves as a warning: the FDA is actively enforcing rules against high-volume commercial copying of popular GLP-1 weight-loss medications under the guise of compounding.
What Is the FDA’s Case Against Empower Pharmacy?
The warning letter outlines critical statutory violations stemming from an inspection of Empower’s Houston facility.
1. Loss of Section 503A Exemptions for Mass Copying
Under Section 503A of the FD&C Act, traditional compounding pharmacies are exempt from three federal requirements (FDA approval under section 505, CGMP under section 501(a)(2)(B), and adequate directions for use under section 502(f)(1)), provided they compound for individually identified patients upon receipt of valid prescriptions and meet the other conditions of section 503A. Crucially, section 503A prohibits pharmacies from compounding drug products “regularly or in inordinate amounts” that are essentially copies of commercially available drugs.
The FDA determined that Empower compounded and filled a redacted number of orders per month for each of the following products between July and October 2025:
- Tirzepatide / Niacinamide
- Semaglutide / Cyanocobalamin
The FDA stated that “the volume of products you are producing suggests that differences between products you are compounding and the FDA-approved products are pretextual.”
Adding a vitamin does not take a GLP-1 product outside the “essentially a copy” analysis. FDA’s April 1, 2026 statement on GLP-1 compounding says a semaglutide and vitamin B12 product is still essentially a copy of the approved drug when the semaglutide and B12 amounts are within 10% of the strengths of the respective commercially available products. The same statement confirms FDA does not intend to take action against a 503A pharmacy that fills four or fewer prescriptions of an essentially copied product in a calendar month. Empower’s volumes were far above that line.
Why commercial availability matters now: FDA removed tirzepatide from its drug shortage list in 2024 (resolution announced October 2, 2024 and reaffirmed December 19, 2024) and semaglutide on February 21, 2025. The enforcement discretion periods for 503A pharmacies ended March 5, 2025 for tirzepatide and April 22, 2025 for semaglutide. Since then, Mounjaro, Zepbound, Ozempic, and Wegovy have been “commercially available,” and copies of them are subject to the section 503A limit.
2. Invalid “Significant Difference” Determinations and Tech Platforms
To qualify as an exemption rather than a “copy,” the change must be made for an identified individual patient and must produce, for that patient, a significant difference from the commercially available drug, as determined by the prescribing practitioner. FDA’s 2018 guidance on essentially copies expects that determination to appear on the prescription itself. FDA inspectors uncovered that Empower was filling prescriptions where:
- Prescriptions lacked any prescriber determination of significant difference.
- Prescriber statements of significant difference were “repeated verbatim across many records,” which FDA said suggested they “may be pre-generated.”
- Prescriptions were generated through third-party technology platforms offering pre-selected drop-down menus for “significant difference” statements, undermining individualized clinical judgment.
By failing 503A exemption conditions, Empower’s compounded GLP-1 formulations lost the exemptions and became subject to the FD&C Act’s new drug approval, labeling, and CGMP requirements. FDA charged them as unapproved new drugs, misbranded for lacking adequate directions for use, and adulterated.
3. Insanitary Conditions and CGMP Violations
The insanitary conditions provision, section 501(a)(2)(A), applies to every compounder regardless of 503A status; the letter says so expressly. The CGMP provision, section 501(a)(2)(B), and 21 CFR Parts 210 and 211 applied here because the products lost 503A protection. Investigators documented conditions that rendered products adulterated:
- Inadequate Airflow Dynamics: Failure to perform adequate smoke studies under dynamic conditions to prove unidirectional airflow within ISO 5 sterile processing areas.
- Flawed Media Fills: Aseptic processing simulations were not performed under challenging conditions. FDA also rejected the firm’s January 2026 corrective media fill because the records did not support the reported vial count, contained unexplained entries, lacked records for certain batches, and showed data transcribed onto new forms without an audit trail explaining who authorized the change and why.
- Environmental & Quality Controls: Inadequate environmental monitoring in aseptic areas, equipment maintenance for aseptic conditions, procedures to prevent microbiological contamination, written production and process controls, and failure of the Quality Control Unit to ensure CGMP compliance.
Tech Platforms and Telemedicine Under the Regulatory Microscope
A notable aspect of the FDA’s enforcement letter is its direct critique of digital order generation and third-party telemedicine software.
The letter states that “generating prescriptions through means that undermine the individualized nature of a prescriber’s clinical judgment (for example through third-party technology platforms that provide prescribers with pre-selected menu options for choosing a statement of significant difference) call the individualized nature of those determinations into question.” FDA did not say a menu-driven statement is invalid in every case. It said such statements, combined with high volume and verbatim repetition, support the conclusion that the stated differences are pretextual.
The letter is addressed to the pharmacy, but the conduct it describes happens at the prescriber and platform level. FDA has not yet issued guidance on how much documentation a prescriber must create to support a significant difference determination, so the letter is the clearest current signal of what the agency will reject.
The takeaway for practitioners: Automated software workarounds designed to streamline bulk GLP-1 prescribing do not protect clinics or pharmacies from federal oversight.
Legal and Operational Risks for Clinics and Prescribers
Medical practices, medspas, and telehealth companies sourcing compounded GLP-1 medications from 503A entities face serious collateral exposure:
- Regulatory and Board Scrutiny: Prescribing unapproved copies of commercial GLP-1 drugs via pre-selected software forms exposes clinicians to state medical board investigations for failing to meet standard-of-care prescribing requirements.
- Product Liability and Malpractice Exposure: Administering or dispensing drugs manufactured under deficient environmental or sterility controls creates civil liability if patients suffer adverse events, infections, or unexpected side effects.
- Supply Chain Disruption: Clinics relying heavily on single compounding suppliers face sudden inventory cutoff when the FDA issues warning letters or moves toward injunctions and product recalls.
What Happens Next
FDA acknowledged Empower’s responses to the inspection findings dated December 8, 2025, March 18, 2026, and April 30, 2026. It found some corrective actions adequate, said it could not fully evaluate others, and found the media fill corrections deficient. Empower had 15 working days from receipt to respond in writing with its corrective steps. A warning letter is not a final agency action, but the letter warns that failure to adequately address the violations may result in legal action without further notice, including seizure and injunction.
Actionable Compliance Steps for Medical Practices
To safeguard your practice and maintain compliance amidst heightened GLP-1 enforcement:
- Audit GLP-1 Sourcing Protocols: Review all compounded GLP-1 medications currently ordered by or prescribed in your practice. Confirm that each product is compounded by a 503A pharmacy for an identified patient under a prescription documenting a patient-specific significant difference. A 503B outsourcing facility is not a workaround: semaglutide and tirzepatide are not on the 503B bulks list and are not in shortage, so outsourcing facilities cannot currently compound them from bulk drug substances.
- Eliminate Boilerplate Prescribing: Ensure prescribers independently evaluate and document patient-specific medical needs when prescribing compounded variations instead of FDA-approved brand-name drugs.
- Review Telehealth Platform Integrations: Audit third-party software forms to ensure they do not auto-populate or nudge prescribers toward pre-selected “significant difference” choices.
- Inspect Supplier Quality: Request and review recent Form FDA 483s, warning letters, and quality documentation from primary compounding vendors.
What This Means for Your Practice
The FDA’s warning letter to Empower Pharmacy is a reminder that the regulatory landscape surrounding compounded GLP-1 medications continues to evolve. For medspa owners, medical directors, healthcare entrepreneurs, and telehealth providers, now is a good time to take a closer look at how your practice sources, prescribes, and documents compounded medications.
At Lengea Law, we help healthcare entrepreneurs navigate the legal and compliance issues that come with operating and growing a healthcare business. Whether you are reviewing your current GLP-1 prescribing practices, working with a compounding pharmacy, evaluating a telehealth platform, or looking for guidance on your overall compliance structure, our team can help you understand the legal considerations and identify areas that may need attention. If you have questions about your current processes, reach out to Lengea Law. We’re here to help you stay informed, compliant, and prepared as the regulatory landscape continues to change.